Tirzepatide

Based on the SURMOUNT-5 head-to-head trial, tirzepatide 15 mg produces significantly more weight loss than semaglutide 2.4 mg — 20.2% vs 13.7% over 72 weeks. Tirzepatide also showed lower rates of GI side effects. However, individual responses vary. Some people respond well to semaglutide and poorly to tirzepatide, or vice versa. The best choice depends on your body, insurance coverage, and how you tolerate each medication.

The maximum FDA-approved dose is 15 mg per week for weight management (Zepbound). The titration schedule takes approximately 20-24 weeks: start at 2.5 mg, increase by 2.5 mg every 4 weeks until reaching 15 mg. However, not everyone needs or tolerates the maximum dose. Many patients achieve significant weight loss at 10 or 12.5 mg with fewer side effects.

Both contain tirzepatide. Mounjaro is approved for type 2 diabetes at doses of 2.5-15 mg. Zepbound is approved for chronic weight management at the same dose range. The medication is identical — the difference is the FDA-approved indication, which affects insurance coverage and prescribing.

Tirzepatide activates two receptors (GIP + GLP-1) while retatrutide activates three (GIP + GLP-1 + glucagon). In Phase 2 data, retatrutide showed up to 24.2% weight loss at 48 weeks, which may exceed tirzepatide when Phase 3 trials are complete. However, retatrutide is not yet FDA-approved and is only available in clinical trials, while tirzepatide is approved and widely available.

Yes, nausea is the most common side effect at 31% in clinical trials — but this is actually lower than semaglutide (44%). Nausea is typically worst during dose escalation and improves over time. The slow titration schedule (increasing by 2.5 mg every 4 weeks) is designed to minimize GI side effects. Taking tirzepatide with a small meal and staying hydrated can help.

In the SURMOUNT-1 trial, participants on tirzepatide 15 mg lost an average of 20.9% of body weight over 72 weeks. For a 250-pound person, that is roughly 52 pounds. Over half of participants at the highest dose lost 20%+ of body weight, and about one-third lost 25%+. When combined with intensive behavioral therapy (SURMOUNT-3), average total weight loss reached 26.6%.

Emerging data suggests tirzepatide may significantly reduce liver fat. The SYNERGY-NASH trial is studying tirzepatide specifically for metabolic dysfunction-associated steatohepatitis (MASH). In the SURMOUNT-2 trial, tirzepatide showed improvements in liver enzyme markers. The glucagon receptor may have direct liver benefits that GLP-1-only drugs lack. Results from SYNERGY-NASH are expected in 2025-2026.

Zepbound (weight management) has a list price of approximately $1,060/month. Mounjaro (diabetes) costs approximately $1,023/month. Eli Lilly offers a manufacturer savings card that can reduce out-of-pocket costs. Insurance coverage varies widely. Some compounding pharmacies offer tirzepatide at lower cost, though supply and legality of compounding vary by state.

Yes. The SURMOUNT-4 trial directly addressed this. After 36 weeks of treatment (average 20.9% weight loss), participants switched to placebo regained 14% body weight over the next 52 weeks, while those who continued treatment maintained their weight loss. Like semaglutide, tirzepatide appears to require ongoing use to maintain results.

Yes, switching is common under medical supervision. Your doctor will typically start you at the lowest tirzepatide dose (2.5 mg) and titrate up, regardless of your semaglutide dose. There is no required washout period. Some patients switch because they plateau on semaglutide or want to try the dual-receptor approach for greater weight loss.